Related Experiment Videos
Prevention of recurrent ischemic stroke
1Neurological Clinic, Minneapolis, MN 55404.
Insights
Focused prophylaxis after ischemic stroke or transient ischemic attack (TIA) targets the cause. Aspirin is standard therapy; carotid endarterectomy is recommended for severe stenosis. Anticoagulants are reserved for progressing strokes.
Area of Science:
- Neurology
- Vascular Medicine
- Preventive Cardiology
Background:
- Ischemic stroke and transient ischemic attack (TIA) management requires targeted prophylaxis based on the underlying cause.
- Degenerative large- and small-vessel disease are common causes of ischemic stroke, necessitating a focus on modifiable risk factors.
- Therapeutic strategies for stroke prevention are evolving, with ongoing research clarifying optimal treatments.
Purpose of the Study:
- To review current evidence for secondary prevention strategies following ischemic stroke and TIA.
- To delineate the role of various pharmacologic and surgical interventions in stroke prophylaxis.
- To provide guidance on managing patients with cerebrovascular disease to reduce recurrent events.
Main Methods:
- Review of scientific data and clinical trial evidence regarding stroke treatment and prevention.
- Analysis of guidelines and expert consensus on managing ischemic stroke and TIA.
- Evaluation of the efficacy and safety of medications such as aspirin, dipyridamole, ticlopidine, and anticoagulants.
- Assessment of surgical interventions like carotid endarterectomy.
Main Results:
- Carotid endarterectomy is strongly supported for severe stenosis (70%-99%) with ipsilateral TIA or nondisabling stroke.
- Aspirin is recommended as standard preventive therapy for all TIA/stroke patients, with 325 mg/day potentially offering less gastrotoxicity than 1,300 mg/day.
- Dipyridamole is not currently warranted; ticlopidine's role is undefined but may be a first-choice drug despite cost and side effects.
- Anticoagulant efficacy is unproven for degenerative cerebrovascular disease but may be prudent for progressing strokes; immediate post-TIA heparin is not indicated.
Conclusions:
- Secondary stroke prevention should be cause-directed, prioritizing modifiable risk factors.
- Aspirin is a cornerstone of therapy, while carotid endarterectomy is indicated for specific severe stenosis cases.
- The use of anticoagulants and newer antiplatelet agents requires careful consideration based on individual patient profiles and ongoing thrombotic risk.
Abstract:
Treatment after an ischemic stroke or transient ischemic attack (TIA) should target the presumed cause of the initial episode to facilitate focused prophylaxis. In the majority of ischemic strokes, degenerative large- and small-vessel disease is the cause. In these patients, attention to modifiable risk factors is an important priority. However, uncertainty and controversy remain regarding therapy, although issues are gradually being settled. There are now strong scientific data to support the use of carotid endarterectomy in patients with 70% to 99% stenosis and an ipsilateral TIA or nondisabling stroke. Aspirin is accepted as standard preventive therapy and should be used in all patients with a TIA or stroke, including those who undergo endarterectomy. Although the dose most commonly used in clinical trials is 1,300 mg/day, a daily dose of 325 mg is probably equally effective with less gastrotoxicity. Given present evidence, use of dipyridamole (Persantine) is not warranted. The role of ticlopidine hydrochloride (Ticlid) in stroke prophylaxis is not well defined. Its superiority over aspirin demonstrated in one study may make it the drug of first choice despite its expense and side effects. The efficacy of warfarin sodium (Coumadin, Panwarfin, Sofarin) or heparin in ischemic stroke caused by degenerative cerebrovascular disease is not supported by scientific data, but no prospective controlled studies have demonstrated that these agents are ineffective. Therefore, it seems prudent to reserve anticoagulant therapy for situations in which an ongoing thrombotic process is likely (eg, progressing stroke). Heparin therapy in the immediate post-TIA period is not warranted on the basis of current scientific evidence.